Inhibition of renal cancer cell growth in vitro and in vivo with oncolytic adenovirus armed short hairpin RNA targeting Ki-67 encoding mRNA

Cancer Gene Therapy

Volumn 16, Issue 1, 2009, Pages 20-32

  Zheng, J N ^a   Pei, D S ^a   Mao, L J ^a   Liu, X Y ^b   Mei, D D ^a   Zhang, B F ^a   Shi, Z ^a   Wen, R M ^a   Sun, X Q ^a  

^a XUZHOU MEDICAL UNIVERSITY   (China)

^b INSTITUTE OF BIOCHEMISTRY AND CELL BIOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; BETA ACTIN; ENHANCED GREEN FLUORESCENT PROTEIN; KI 67 ANTIGEN; MESSENGER RNA; ONCOLYTIC ADENOVIRUS; SHORT HAIRPIN RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CARCINOMA; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; NUDE MOUSE; PLASMID; PRIORITY JOURNAL; RNA INTERFERENCE; TUMOR CELL; VIRAL GENE THERAPY; VIRUS REPLICATION;

ADENOVIRIDAE; ANIMALS; APOPTOSIS; CELL LINE, TUMOR; GENE KNOCKDOWN TECHNIQUES; GENE THERAPY; HUMANS; KI-67 ANTIGEN; KIDNEY NEOPLASMS; MICE; MICE, NUDE; NEOPLASM PROTEINS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; RNA INTERFERENCE; RNA, MESSENGER; RNA, NEOPLASM; RNA, SMALL INTERFERING; VIRUS REPLICATION;

ADENOVIRIDAE; MUS MUSCULUS;

EID: 57649135364     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2008.61     Document Type: Article

References (44)

1. MacCallum DE, Hall PA. Biochemical characterization of pKi67 with the identification of a mitotic-specific form associated with hyperphosphorylation and altered DNA binding. Exp Cell Res 1999; 252: 186-198.
2. Endl E, Gerdes J. The Ki-67 protein: fascinating forms and an unknown function. Exp Cell Res 2000; 257: 231-237.
3. Du Manoir S, Guillaud P, Camus E, Seigneurin D, Brugal G. Ki-67 labeling in postmitotic cells defines different Ki-67 pathways within the 2c compartment. Cytometry 1991; 12: 455-463.
4. Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 1984; 133: 1710-1715.
5. Endl E, Gerdes J. Posttranslational modifications of the Ki67 protein coincide with two major checkpoints during mitosis. J Cell Physiol 2000; 182: 371-380.
6. Endl E, Gerdes J. The Ki-67 protein: fascinating forms and an unknown function. Exp Cell Res 2000; 257: 231-237.
7. Rioux-Leclercq N, Turlin B, Bansard JY, Patard J, Manunta A, Moulinoux JP et al. Value of immunohistochemical Ki-67 and p53 determinations as predictive factors of outcome in renal cell carcinoma. Urology 2000; 55: 501-505.
8. Visapaä H, Bui M, Huang Y, Seligson D, Tsai H, Pantuck A et al. Correlation of Ki-67 and gelsolin expression to clinical outcome in renal clear cell carcinoma. Urology 2003; 61: 845-850.
9. Kausch I, Jiang H, Ewerdwalbesloh N, Doehn C, Kruger S, Sczakiel G et al. Inhibition of Ki-67 in a renal cell carcinoma severe combined immunodeficiency disease mouse model is associated with induction of apoptosis and tumour growth inhibition. BJU Int 2005; 95: 416-420.
10. Glunde K, Raman V, Mori N, Bhujwalla ZM. RNA interference-mediated choline kinase suppression in breast cancer cells induces differentiation and reduces proliferation. Cancer Res 2005; 65: 11034-11043.
11. Devi G. siRNA-based approaches in cancer therapy. Cancer Gene Ther 2006; 13: 819-829.
12. Kennerdell JR, Carthew RW. Use of dsRNA-mediated genetic interference to demonstrate that frizzled and frizzled 2 act in the wingless pathway. Cell 1998; 905: 1017-1026.
13. Brummelkamp TR, Bernards R, Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science 2002; 296: 550-553.
14. Zheng JN, Ma TX, Cao JY, Sun XQ, Chen JC, Li W et al. Knockdown of Ki-67 by small interfering RNA leads to inhibition of proliferation and induction of apoptosis in human renal carcinoma cells. Life Sci 2006; 78: 724-729.
15. Zheng JN, Sun YF, Pei DS, Liu JJ, Ma TX, Han RF et al. Treatment with vector-expressed small hairpin RNAs against Ki67 RNA induced cell growth inhibition and apoptosis in human renal carcinoma cells. Acta Biochimica et Biophysica Sinica 2006; 38: 254-261.
16. Uchida H, Tanaka T, Sasaki K, Kato K, Dehari H, Ito Y et al. Adenovirus-mediated transfer of siRNA against survivin induced apoptosis and attenuated tumor cell growth in vitro and in vivo. Mol Ther 2004; 10: 162-171.
17. Yoo JY, Kim JH, Kwon YG, Kim EC, Kim NK, Choi HJ et al. VEGF-specific short hairpin RNA-expressing oncolytic adenovirus elicits potent inhibition of angiogenesis and tumor growth. Mol Ther 2007; 15: 295-302.
18. Heise C, Kirn D. Replication-selective adenoviruses as oncolytic agents. J Clin Invest 2000; 105: 847-851.
19. Bischoff J, Kirn D, Williams A, Heise C, Horn S, Muna M et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 1996; 274: 373-376.
20. Hay J, Shapiro N, Sauthoff H, Heitner S, Phupakdi W, Rom W. Targeting the replication of adenoviral gene therapy vectors to lung cancer cells: the importance of the adenoviral E1b-55kD gene. Hum Gene Ther 1999; 10: 579-590.
21. Khuri F, Nemunaitis J, Ganly I, Arseneau J, Tannock I, Romel L et al. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med 2000; 6: 879-885.
22. Zhang ZL, Zou WG, Luo CX, Li BH, Wang JH, Sun LY et al. An armed oncolytic adenovirus system, ZD55-gene, demonstrating potent antitumoral efficacy. Cell Res 2003; 13: 481-489.
23. Qi R, Gu J, Zhang Z, Yang K, Li B, Fan J et al. Potent antitumor efficacy of XAF1 delivered by conditionally replicative adenovirus vector via caspase-independent apoptosis. Cancer Gene Ther 2007; 14: 82-90.
24. Zhang Y, Gu J, Zhao L, He L, Qian W, Wang J et al. Complete elimination of colorectal tumor xenograft by combined manganese superoxide dismutase with tumor necrosis factor-related apoptosis-inducing ligand gene virotherapy. Cancer Res 2006; 66: 4291-4298.
25. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C et al. Cancer statistics, 2006. CA Cancer J Clin 2006; 56: 106-130.
26. Mulders P, Figlin R, deKernion JB, Wiltrout R, Linehan M, Parkinson D et al. Renal cell carcinoma: recent progress and future directions. Cancer Res 1997; 57: 5189-5195.
27. Karagiannis TC, El-Osta A. RNA interference and potential therapeutic applications of short interfering RNAs. Cancer Gene Ther 2005; 12: 787-795.
28. Shen C, Buck AK, Liu X, Winkler M, Reske SN. Gene silencing by adenovirus-delivered siRNA. FEBS Lett 2003; 539: 111-114.
29. Zhao LJ, Jian H, Zhu H. Specific gene inhibition by adenovirus-mediated expression of small interfering RNA. Gene 2003; 316: 137-141.
30. Dobbelstein M. Replicating adenoviruses in cancer therapy. Curr Top Microbiol Immunol 2004; 273: 291-334.
31. Jounaidi Y, Doloff JC, Waxman DJ. Conditionally replicating adenoviruses for cancer treatment. Curr Cancer Drug Targets 2007; 7: 285-301.
32. Ries S, Korn WM. ONYX-015: mechanism of action and clinical potential of replication-selective adenovirus. Br J Cancer 2002; 86: 5-11.
33. Heise C, Kirn DH. Replication-selective adenoviruses as oncolytic agents. J Clin Invest 2000; 105: 847-851.
34. Nemumaitis J, Ganly I, Khuri F, Arseneau J, Kuhn J, McCarty T et al. Selective replication oncolysis in p53 mutant tumours with ONYX-015, an E1B-55kDa gene deleted adenovirus, in patients with advanced head and neck cancer: a phase II trail. Cancer Res 2000; 60: 6359-6366.
35. Nemumaitis J, Khuri F, Ganly I, Arseneau J, Posner M, Vokes E et al. Phase II trail of intratumoral administration of ONYX-015, a replication-selective adenovirus in patients with refractory head and neck cancer. J Clin Oncol 2001; 19: 289-298.
36. Hermiston T. Gene delivery from replication-selective viruses: arming guided missiles in the war against cancer. J Clin Invest 2000; 105: 1169-1172.
37. Zhao L, Gu J, Dong A, Zhang Y, Zhong L, He L et al. Potent antitumor activity of oncolytic adenovirus expressing mda-7/IL-24 for colorectal cancer. Hum Gene Ther 2005; 16: 845-858.
38. Liu XY, Gu JF. Targeting gene-virotherapy of cancer. Cell Res Jan 2006; 16: 25-30.
39. Liu XY, Qiu SB, Zou WG, Pei ZF, Gu JF, Luo CX et al. Effective gene-virotherapy for complete eradication of tumor mediated by the combination of hTRAIL (TNFSF10) and plasminogen k5. Mol Ther 2005; 11: 531-541.
40. Carette JE, Overmeer RM, Schagen FH, Alemany R, Barski OA, Gerritsen WR et al. Conditionally replicating adenoviruses expressing short hairpin RNAs silence the expression of a target gene in cancer cells. Cancer Res 2004; 64: 2663-2667.
41. Zhang YA, Nemunaitis J, Samuel SK, Chen P, Shen Y, Tong AW. Antitumor activity of an oncolytic adenovirus-delivered oncogene small interfering RNA. Cancer Res 2006; 66: 9736-9743.
42. Kausch I, Jiang H, Ewerdwalbesloh N, Doehn C, Krüger S, Sczakiel G et al. Inhibition of Ki-67 in a renal cell carcinoma severe combined immunodeficiency disease mouse model is associated with induction of apoptosis and tumour growth inhibition. BJU Int 2005; 95: 416-420.
43. Tong AW, Zhang YA, Nemunaitis J. Small interfering RNA for experimental cancer therapy. Curr Opin Mol Ther 2005; 7: 114-124.
44. Bauzon M, Castro D, Karr M, Hawkins LK, Hermiston TW. Multigene expression froma replicating adenovirus using native viral promoters. Mol Ther 2003; 7: 526-534.